Duloxetine
From Proteopedia
(Difference between revisions)
Line 5: | Line 5: | ||
In vitro binding studies using synaptosomal preparations isolated from rat cerebral cortex indicated that duloxetine was approximately 3 fold more potent at inhibiting serotonin uptake than norepinephrine uptake.<ref name="a64">PMID:28913467</ref> | In vitro binding studies using synaptosomal preparations isolated from rat cerebral cortex indicated that duloxetine was approximately 3 fold more potent at inhibiting serotonin uptake than norepinephrine uptake.<ref name="a64">PMID:28913467</ref> | ||
+ | |||
+ | <scene name='97/975936/Cv/2'>Sodium-dependent dopamine transporter in S-duloxetine bound form</scene> ([[6m38]]). | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 12:15, 12 July 2023
|
References
- ↑ Stahl S (2013). Stahl's Essential Pharmacology (4th ed.). New York: Cambridge University Press. pp. 305, 308, 309.
- ↑ Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005 Sep;10(9):732-47. PMID:16142213 doi:10.1017/s1092852900019726
- ↑ Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93. PMID:15892657 doi:10.2174/1381612053764805
- ↑ Onuţu AH. Duloxetine, an antidepressant with analgesic properties Rom J Anaesth Intensive Care. 2015 Oct;22(2):123-128 PMID:28913467